Lung Cancer, NSCLC
Conditions
Keywords
Lung cancer, Cytotoxic lymphocyte, LC-CTL, NSCLC
Brief summary
The primary objective of this study is to evaluate the safety of lung cancer specific cytotoxic lymphocytes (LC-CTLs). The secondary objectives are to evaluate the rate of successful LC-CTLs generation in vitro and determine the anti-lung cancer efficacy.
Detailed description
Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. The two main types are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). Worldwide in 2012, lung cancer occurred in 1.8 million people and resulted in 1.6 million deaths. Common treatments include surgery, chemotherapy, and radiotherapy. Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific viral antigens has proven to be effective. Here, the investigators aim to evaluate the safety and efficacy of multiple infusions of lung cancer specific cytotoxic T lymphocytes cells in patients.
Interventions
BIOLOGICALLC-CTLs
2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
Sponsors
Shenzhen Geno-Immune Medical Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Written, informed consent obtained prior to any study-specific procedures. 2. Age older than 18 years. 3. Patients with refractory, relapsed, metastatic, advanced lung cancer confirmed by histology and biopsy. 4. Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. 5. Expected survival ≥ 12 weeks. 6. Not pregnant, and on appropriate birth control if of childbearing potential. 7. Initial hematopoietic reconstitution with * neutrophils (ANC) ≥ 1,000/mm\^3; * platelet (PLT) ≥ 100,000/mm\^3. 8. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with * serum creatinine ≤ 2×ULN; * serum bilirubin ≤ 2×ULN; * AST/ALT ≤ 2×ULN; * ALKP ≤ 5×ULN; * serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome. 9. Human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) test were negative.
Exclusion criteria
1. Have occurred in 5 years or are currently suffering from other cancers, except for cured cervical cancer, non-melanoma skin cancer and superficial bladder cancer. 2. Previous exposure to mouse CEA antibody. 3. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in this study. 4. Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations). 5. Pregnant or lactating females. 6. Inadequate bone marrow function with * absolute neutrophil count \< 1,000/mm\^3; * platelet count \< 100,000/mm\^3; * Hb \< 9 g/dL. 7. Inadequate liver and renal function with * serum (total) bilirubin \> 1.5 x ULN; * AST \& ALT \> 2.5 x ULN (\> 5 x ULN in patients with liver metastases); * alkaline phosphatase \> 2.5 x ULN; * serum creatinine \>2.0 mg/dl (\> 177 μmol/L); * urine dipstick for protein uria should be \< 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate \< 1 g of protein/24 hr. 8. Serious active infection requiring i.v. antibiotics at during screening. 9. Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of LC-CTLs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events | 3 months | Physiological parameter (measuring cytokine response) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Functional analyses of LC-CTLs in vitro | 2 weeks | The specificity of LC-CTLs in vitro will be analysed by intracellular cytokine staining (ICCS) or enzyme-linked immunospot assay (ELISPOT). |
| Anti-tumor effects | 1 year | Biochemical markers and image scan will be got before and after treatment. Objective response, such as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORLung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Outcome results
None listed